Overview

This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.

Eligibility

Inclusion Criteria:

• Fully understand the study and voluntarily sign the informed consent form.
• Male or female 18-75 years of age;
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
• Life expectancy ≥ 12 weeks;
• Histologically or cytologically confirmed diagnosis of advanced solid tumors.

Exclusion Criteria:

• Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
• Any other malignancy within 5 years.